229476-53-3 Usage
Description
EBE-A 22 is a compound that functions as an epidermal growth factor receptor (EGFR) inhibitor and a selective VEGFR-2 receptor tyrosine kinase inhibitor. These properties make it a significant molecule in the field of cancer treatment, as it targets key pathways involved in cancer cell growth and angiogenesis.
Uses
Used in Pharmaceutical Industry:
EBE-A 22 is used as an anticancer agent for targeting the epidermal growth factor receptor (EGFR) and the selective VEGFR-2 receptor tyrosine kinase. Its application is particularly relevant in the treatment of various types of cancer, as it can inhibit the growth and proliferation of cancer cells by disrupting these critical signaling pathways.
Additionally, EBE-A 22's role as a selective VEGFR-2 inhibitor makes it a potential candidate for use in therapies aimed at reducing angiogenesis, the process by which tumors develop their blood supply. This can help to limit the growth and spread of cancerous cells.
Check Digit Verification of cas no
The CAS Registry Mumber 229476-53-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,9,4,7 and 6 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 229476-53:
(8*2)+(7*2)+(6*9)+(5*4)+(4*7)+(3*6)+(2*5)+(1*3)=163
163 % 10 = 3
So 229476-53-3 is a valid CAS Registry Number.
229476-53-3Relevant articles and documents
Impact of aryloxy-linked quinazolines: A novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors
Garofalo, Antonio,Goossens, Laurence,Six, Perrine,Lemoine, Amélie,Ravez, Séverine,Farce, Amaury,Depreux, Patrick
, p. 2106 - 2112 (2011/04/24)
Three series of 6,7-dimethoxyquinazoline derivatives substituted in the 4-position by aniline, N-methylaniline and aryloxy entities, targeting EGFR and VEGFR-2 tyrosine kinases, were designed and synthesized. Pharmacological activities of these compounds
